MedPath

Idys™ TLIF 3DTi Post Market Clinical Follow-up

Conditions
Degenerative Disc Disease
Grade 1 Spondylolisthesis
Registration Number
NCT04584619
Lead Sponsor
Clariance
Brief Summary

The aim of this observational post-marketing study is to provide additional information on the safety and effectiveness of Idys™ TLIF 3DTi at up to 24 months post transforaminal lumbar fusion in usual surgical practice.

Detailed Description

The primary endpoint is to evaluate the effectiveness of the Idys™ TLIF (Transforaminal Lumbar Interbody Fusion) 3DTi (Porous Titanium additive manufacturing) by measuring the evolution of the rate of fusion during the postoperative period.

The secondary endpoints are to analyze the safety and the patient's benefit of the Idys™ TLIF 3DTi by evaluating several point of view:

* The adverse events related to the surgery;

* The functional improvement between preoperative state and the different follow-up time points using the Oswestry Disability Index (ODI);

* The improvement of back pain between preoperative state and the different follow-up time points using the Visual Analog Scale (VAS) (legs and back);

* The evolution of several radiologic lumbar parameters to assess the correction and its stability.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
25
Inclusion Criteria
  • English Speaking patients

  • Patient with skeletal maturity

  • Patient with

    • degenerative disc disease at one or two levels from L2 to S1 and/or
    • grade 1 spondylolisthesis
  • Surgical treatment with Idys TLIF 3DTi interbody fusion device used in conjunction with a posterior fixation system (pedicle screws and rod).

Exclusion Criteria
  • Off-label indications.
  • Any medical or surgical condition which would preclude the potential benefit of spinal implant surgery.
  • Any patient having a prior fusion at the level to be treated.
  • Any patient being vulnerable
  • Non-English speakers

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evolution of the Fusion rate6 months, 12 months, 24 months postoperatively

Evolution of the radiological assessment of bony fusion at 3 different time point

Secondary Outcome Measures
NameTimeMethod
Evolution of the Patient PainPreoperatively and then 6 weeks, 6 months, 12 months and 24 months postoperatively

Assessment, at different time points, of the pain using Visual Analogue Scale (range 0 to 10 with higher scores meaning a worse outcome)

Radiologic Outcomes - Stability of the Idys TLIF 3DTi Device6 weeks, 6 months, 12 months and 24 months postoperatively

Measurement ,on x-rays at different time points, of the anterior position of the Idys TLIF 3DTi device

Radiologic Outcomes - Evolution of the lordosis angles (degree)Preoperatively and then 6 weeks, 6 months, 12 months and 24 months postoperatively

Measurements, on x-rays at different time points, of the lordosis angle at pathological / implanted level and of the global lordosis angle between L1/S1

Adverse eventsUp to 24 months postoperatively

To quantify and describe adverse events

Evolution of the Patient DisabilityPreoperatively and then 6 weeks, 6 months, 12 months and 24 months postoperatively

Assessment, at different time points, of the disability using Oswestry Disability Index score (range 0 to 100 with zero corresponding to no disability and 100 corresponding to the maximum disability possible)

Radiologic Outcomes - Evolution of the Intervertebral Height (mm)Preoperatively and then 6 weeks, 6 months, 12 months and 24 months postoperatively

Measurements, on x-rays at different time points, of the anterior and the posterior inter-vertebral height.

Trial Locations

Locations (1)

Brazos Spine

🇺🇸

College Station, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath